Cannabidiol (Epidiolex)
Small molecule
Also known as GWP42003
Evidence outlook
Approved: Epilepsy, Lennox-Gastaut Syndrome, Dravet Syndrome, Developmental and Epileptic Encephalopathies
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (2)
- Treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older
- Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
GWPCARE5 NCT02224573 · Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome This is a genuine open-label extension trial: the title explicitly states 'Open Label Extension Study,' and eligibility required participants to have completed the treatment phase of the prior randomized, double-blind, placebo-controlled core studies (NCT02091206, NCT02091375, NCT02224703, NCT02224560, NCT02224690). It used a single group of 681 participants with no randomization, no blinding, and no comparator arm, so it cannot provide comparative evidence on its own. The primary outcomes were mostly safety measures plus descriptive changes in seizure frequency, and no inferential statistical comparison was conducted. Registry: NCT02224573 | 3 | Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment Group (up to Week 260); Number of Participants With Clinically Significant Changes in the Indicated Vital Sign Values From the Pre-randomization Baseline of the Core Study at Any Time Post-dose (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Body Mass Index (BMI) (up to Week 260); Number of Participants With Clinically Significant Electrocardiogram (ECG) Values at the Pre-randomization Baseline of the Core Study and at Any Time Post-dose (up to Week 260); Number of Participants With the Indicated Responses to Questions Regarding Suicidal Ideation and Behavior Using the Children's Columbia-Suicide Severity Rating Scale (C-SSRS) at Day 1 and at Any Time Post-dose (up to Week 260); Mean Cannabis Withdrawal Scale Score at End of Taper (EOT), the Post-Taper Safety Call, and at Safety Follow-up (up to Week 260); Mean Pediatric Cannabinoid Withdrawal Scale (PCWS) Score at the End of Treatment, the End of Taper, the Post-Taper Safety Call, and at Safety Follow-up (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Red Blood Cells (RBCs) Values (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Hemoglobin Levels (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Hematocrit Values (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Erythrocyte Mean Corpuscular Volume (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Erythrocyte Mean Corpuscular Hemoglobin (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Platelets, White Blood Cells, Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in the Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils in White Blood Cells (WBCs) (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Sodium, Potassium, Blood Urea Nitrogen, Glucose, Calcium, and High-Density Lipoprotein (HDL) Cholesterol (up to week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Creatinine (Jaffe), Creatinine (Enzymatic), and Bilirubin (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Creatinine Clearance (Schwartz) and Creatinine Clearance (Cockcroft-Gault) (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase, and Gamma Glutamyl Transferase (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Albumin and Protein (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prolactin (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prothrombin Time (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prothrombin International Normalized Ratio (up to Week 260); Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Insulin-like Growth Factor-1 (IGF-1) Levels (up to Week 260); Mean Subject/Caregiver Global Impression of Change (S/CGIC) Score (Baseline; up to Week 260); Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Total Seizure Frequency (Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, Week 253 to 264, and Last 12 Weeks); Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Drop Seizure Frequency in Participants With Lennox-Gastaut Syndrome (Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, and Last 12 Weeks); Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Convulsive Seizure Frequency in Participants With Dravet Syndrome (Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, Week 253 to 264, and Last 12 Weeks); Number of Participants With Convulsive and Non-convulsive Seizures Greater Than 30 Minutes in Duration (Status Epilepticus) (Baseline; At last 12 weeks) 2020-09-24 | Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment Group (up to Week 260): Dravet Syndrome — Total participants affected by any TEAE: 306 participants; Diarrhoea: 135 participants; Vomiting: 63 participants; Constipation: 20 participants; Nausea: 16 participants; Pyrexia: 124 participants; Fatigue: 39 participants; Upper respiratory tract infection: 78 participants; Nasopharyngitis: 78 participants; Sinusitis: 38 participants; Pneumonia: 35 participants; Ear infection: 35 participants; Influenza: 37 participants; Urinary tract infection: 19 participants; Pharyngitis streptococcal: 26 participants; Gastroenteritis viral: 15 participants; Otitis media: 21 participants; Bronchitis: 15 participants; Viral upper respiratory tract infection: 11 participants; Gastroenteritis: 16 participants; Fall: 22 participants; Laceration: 8 participants; Contusion: 15 participants; Weight decreased: 21 participants; Alanine aminotransferase increased: 37 participants; Aspartate aminotransferase increased: 38 participants; Gamma-glutamyltransferase increased: 32 participants; Decreased appetite: 99 participants; Convulsion: 79 participants; Somnolence: 87 participants; Status epilepticus: 47 participants; Lethargy: 21 participants; Headache: 18 participants; Sedation: 16 participants; Drooling: 11 participants; Abnormal behaviour: 34 participants; Insomnia: 16 participants; Irritability: 26 participants; Aggression: 20 participants; Agitation: 9 participants; Cough: 42 participants; Nasal congestion: 13 participants; Rhinorrhoea: 20 participants; Pneumonia aspiration: 4 participants; Hypoxia: 2 participants | Lennox-Gastaut Syndrome — Total participants affected by any TEAE: 353 participants; Diarrhoea: 140 participants; Vomiting: 107 participants; Constipation: 43 participants; Nausea: 32 participants; Pyrexia: 126 participants; Fatigue: 38 participants; Upper respiratory tract infection: 104 participants; Nasopharyngitis: 58 participants; Sinusitis: 49 participants; Pneumonia: 51 participants; Ear infection: 50 participants; Influenza: 45 participants; Urinary tract infection: 51 participants; Pharyngitis streptococcal: 27 participants; Gastroenteritis viral: 30 participants; Otitis media: 22 participants; Bronchitis: 23 participants; Viral upper respiratory tract infection: 20 participants; Gastroenteritis: 7 participants; Fall: 23 participants; Laceration: 35 participants; Contusion: 25 participants; Weight decreased: 61 participants; Alanine aminotransferase increased: 30 participants; Aspartate aminotransferase increased: 19 participants; Gamma-glutamyltransferase increased: 20 participants; Decreased appetite: 93 participants; Convulsion: 141 participants; Somnolence: 107 participants; Status epilepticus: 42 participants; Lethargy: 34 participants; Headache: 26 participants; Sedation: 27 participants; Drooling: 21 participants; Abnormal behaviour: 23 participants; Insomnia: 40 participants; Irritability: 29 participants; Aggression: 30 participants; Agitation: 19 participants; Cough: 63 participants; Nasal congestion: 46 participants; Rhinorrhoea: 19 participants; Pneumonia aspiration: 22 participants; Hypoxia: 21 participants | Partial signal | link ↗ |
View 5 more trials
GWPCARE6 NCT02544750 · Tuberous Sclerosis Complex, Seizures This was a single-group, open-label extension of the completed double-blind GWEP1521 trial (NCT02544763), with 199 participants continuing into cannabidiol treatment and no concurrent placebo or active-control arm. The primary outcomes were safety measures, so the reported seizure findings were secondary and descriptive rather than a randomized primary-endpoint comparison. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT02544750 | 3 | Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE) (OLE Day 1 up to 4 years); Number of Participants With Any TEAE, by Severity (OLE Day 1 up to 4 years) 2021-06-11 | Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE) (OLE Day 1 up to 4 years): GWP42003-P (Double-blind Phase) — Any TEAE: 117 Participants; Any treatment-related TEAE: 80 Participants; Any TEAE leading to permanent discontinuation of IMP: 11 Participants; Any treatment-related TEAE leading to permanent discontinuation of IMP: 9 Participants; Any serious TEAE: 38 Participants; Any treatment-related serious TEAE: 7 Participants; Any fatal TEAEs: 1 Participants | Placebo (Double-blind Phase) — Any TEAE: 75 Participants; Any treatment-related TEAE: 60 Participants; Any TEAE leading to permanent discontinuation of IMP: 7 Participants; Any treatment-related TEAE leading to permanent discontinuation of IMP: 7 Participants; Any serious TEAE: 18 Participants; Any treatment-related serious TEAE: 8 Participants; Any fatal TEAEs: 0 Participants | Weak signal | link ↗ |
GWPCARE1 NCT02091375 · Epilepsy, Dravet Syndrome This was a randomized, quadruple-blind, placebo-controlled trial of 120 participants (61 receiving cannabidiol and 59 placebo) using convulsive seizure frequency as its primary clinical endpoint. The primary comparison was met: median seizure frequency fell 38.94% with cannabidiol versus 13.29% with placebo, with p=0.0123. Registry: NCT02091375 | 3 | Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)) 2015-11-26 | Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | Reliable signal | link ↗ |
GWPCARE4 NCT02224690 · Epilepsy Participants were randomized to cannabidiol (86) or matching placebo (85), with participants, caregivers, investigators, and outcome assessors blinded. The primary seizure-frequency endpoint was statistically met in favor of cannabidiol (p=0.0135), but no primary-endpoint power calculation is reported in the available sources, so the evidence is graded as moderate rather than strong. Registry: NCT02224690 | 3 | Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)) 2016-03-18 | Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -43.9 percentage change (IQR -69.62 to 1.93) vs Placebo -21.8 percentage change (IQR -45.72 to 1.74) | Partial signal | link ↗ |
GWPCARE3 NCT02224560 · Epilepsy This was a randomized, quadruple-blind, placebo-controlled trial with 225 participants, and its clinical primary endpoint—change in drop-seizure frequency—was statistically significantly better with both cannabidiol doses than placebo. The registry does not report the sample-size or power calculation, so the evidence is considered moderate rather than strong despite the favorable result. Registry: NCT02224560 | 3 | Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)) 2016-05-19 | Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -41.86 percentage change (IQR -72.4 to -1.3) | GWP42003-P 10 mg/kg/Day Dose -37.16 percentage change (IQR -63.8 to -5.6) vs Placebo -17.17 percentage change (IQR -37.1 to 0.9) | Partial signal | link ↗ |
GWPCARE6 NCT02544763 · Epilepsy Patients were randomly assigned to one of two cannabidiol doses or a matching placebo, with patients, caregivers, doctors and assessors blinded. The trial planned 210 patients from a stated power calculation and enrolled 224, and both doses significantly reduced seizures compared with placebo (median reductions of 43.4% and 36.6% versus 20.1%; p=0.0009 and p=0.0018). Registry: NCT02544763 | 3 | Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16) 2019-01-22 | Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (31)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (5)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Studied as part of a combination product (1)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 2/3 (1)
What this study did
Appears in other studies (204)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (83)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (44)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (26)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other cannabinoid drugs
Cannabidiol (JZP926), Cannabidiol (Kanbis). Compare all 3 cannabinoid drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cannabidiol (Epidiolex): this drug | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Reliable signal | NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | Reliable signal | NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) | |
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | not yet graded | No reviewed efficacy summary in this indication | |
| Fenfluramine (Fintepla) | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001). NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) | |
| Ganaxolone | Approved | Small molecule | GABA-A receptor | Partial signal | NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022). | |
| Rufinamide | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Stiripentol | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Vigabatrin (Sabril) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Vigabatrin (Vigafyde) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Relutrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (persistent current) | not yet graded | No reviewed efficacy summary in this indication | |
| BMB-101 | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(22 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cannabidiol (Epidiolex) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.